High throughput chemical file screening with an enzymatic assay to detect inhibitors of the ErmC methyltransferase enzyme from macrolide-lincosamide-streptogramin B (MLSB) resistant pathogenic bacteria identified low molecular weight compounds that had IC5Os (50% inhibitory concentration) in the nMolar to^Molar range. These sameinhibitors were assessed in vitro for their capacity to inhibit the liver enzyme,cathechol-0-methyltransferase and the prokaryotic enzyme, EcoBl methylase. Selective inhibitors of the ErmC methyltransferase were tested in tertiary assays to determine their minimal inhibitory concentrations (MICs), as single agents and in combination with the macrolide, azithromycin, against strains of pathogenic bacteria expressing MLSB-resistance. Compoundsthat were active in vitro, alone or in combination with azithromycin, against strains of macrolide-resistant pathogens were tested in a mouse model of infection using an MLSB-resistant strain of Staphylococcusaureus or a macrolide-susceptible strain of Streptococcus pyogenes.
antibiotics have distinct chemical structures but have been shown to have a similar mechanismof action against bacteria. They inhibit peptidyltransferase reactions in vitro and are inhibitors of peptide bond formation in whole cells1 >2). The first macrolides, largely fermentation products, were narrow to medium-spectrum antibiotics with in vitro potency mainly against Gram-positive bacteria, including streptococci, staphylococci and some anaerobes. The lincosamide, clindamycin, was also used extensively against anaerobic bacteria. The newer macrolides, azithromycin and clarithromycin, are semisynthetic derivatives with expanded activities against certain Gram-negative bacterial species, especially Haemophilus influenzae and Neisseria gonorrhoeae.
Resistance to these antibiotics emerged within a few years of their introduction as therapeutic agents. The most widespread mechanism of macrolide and lincosamide- eight classes of erm geries as determined by nucleic acid hybridization analyses and nucleotide sequencecomparisons; they show a significant amount of amino acid identity, suggesting that they are derived from a common ancestor. The methylases from Gram-positive bacterial pathogens, for example, are more than 50% identical in amino acid sequence5*. Consensus primers to conserved regions of the erm methylase genes are sufficient to allow detection of all erm genes in populations of bacteria by the polymerase chain reaction6).
The ErmCenzyme has been most extensively characterized. It exists in solution as a 29kDa monomeric protein which, in the bacterial cell, is largely bound to ribosomes. Methylation in whole cells specified by several related Erm methylases (ErmC, ErmD, ErmAm,and ErmE) inhibits methylation in vitro by the ErmC methylase, suggesting that these enzymes modify the same site on rRNA7). While there are few published studies of the effect of inhibitors, these enzymes, like manytransmethylases, have an absolute requirement for the methyl donor, S-adenosyl methionine (AdoMet).
Analogues of AdoMet such as adenosine and S-adenosylhomocysteine (SAH) are highly inhibitory8>9). The
ErmC methylase also appears to be highly specific for domains of its second substrate, the 23S rRNA. Studies suggest that the enzyme-23S rRNA complex has a dissociation constant of 4 x 10~9m with a kon and ko ff of4x 106m~1s"1 and 6.8x lO~2s~1, respectively10*.
High throughput screening of synthetic compounds was initiated in order to detect specific inhibitors of the ErmCmethylase that could be used in combination with a broad-spectrum macrolide antibiotic for treatment of infections caused by MLSB-resistant pathogenic bacteria.
Such a combination could be used in humanpopulations against macrolide-susceptible and resistant bacteria to extend the efficacy ofmacrolide, lincosamide and streptogramin B antibiotics, in muchthe same way that jSlactam, /Mactamase inhibitor combinations are presently used. Such inhibitors were detected and their IC5Os for the ErmCmethylase determined, as was their selectivity for this, as opposed to two other transmethylation enzymes, the catechol-Omethyltransferase from rat liver and the EcoRl methylase from E. coli. Finally, their capacity to inhibit MLSB-resistant pathogenic bacteria in vitro, and in some cases in vivo, was assessed. 
Materials and Methods

Chemicals and Other Reagents
EcoRl Methylase Assay
For each assay, 2.0 fi\ (0.5 jug) linear pBR322 was added to 2.5fA of 320/iM AdoMet in 5x methylase buffer (250him NaCl, 250him Tris-HCl pH 8.0 and 50him EDTA), 3.5 fA of inhibitor diluted to desired concentration, and 2.0/A (0.5 unit) of EcoRl methylase in a final volume of 10/d. The assay tube was incubated at 37°C for 1 hour. A 'no inhibitor' and a 'no methylkse' control were included in each assay. The reaction was terminated by heating to 65°C for 10 minutes. The pBR322 template DNAwas digested with EcoRl restriction endonuclease by standard methods. 17 jA of3 x agarose gel buffer with 0.25% bromphenol blue and 3% glycerol14) was added to each reaction tube. 20/xl of this mixture was electrophoresed in a 1.0% agarose gel using 1 x TAE running buffer14). 20 /d of Hind///-digested X DNA was added to a separate well to serve as size marker. The samples were electrophoresed for 1 hour at 50mAand the DNAsamples were visualized by photography of ethidium bromide-stained gels. For this assay, complete inhibition of the methylation reaction resulted in the formation of two bands at 2.30Kb and 2.06Kb, and no RH110(Tn916zlE) and Group B streptococcal strain were grown in 5/ig/ml erythromycin to select against loss of the macrolide-resistance phenotype, while E. coli V854 was grown in 10 /ig/ml erythromycin. Frozen stocks were prepared by mixing 600 /A of an overnight culture of each strain with 400jllI of 50%glycerol. Replicate stocks were frozen at -70°C. 25^1 of thawed working stock was inoculated into 10ml ofBHI broth and incubated overnight at 37°C with shaking. E. faecalis RH110 (Tn916zlE) and the streptococcal strain COH31-46(Tn916zlE) were grown in BHI with 5//g/ml erythromycin. In the morning, strains were removed from the incubator and their turbidities at A600 were determined, using BHI as a blank. Each of these strains achieved turbidities of 0.3 to 0.5 under these conditions.
Preparation of Microtiter Plates
The MICdeterminations were performed in microtiter plates, using a separate plate for each test compound.A Cetus Pro/Pette (Perkin-Elmer) was used to serially dilute the azithromycin in wells Al to HI across the wells through column 7. Test compounds were two-fold serially diluted in BHI in test tubes. With a multichannel pipettor, 50/A of the first dilution of test compound was added 1275 to Al through A7. Additions were continued in this manner through well G7. One well was filled with 200 /^l BHI to serve as a media sterility control well. A second well was filled with 100//I BHI and 100//I of the test strain to serve as a bacterial growth control. Additional wells contained 150ja\ BHI and 50jjI of azithromycin or test compoundstock solution as controls for compound and azithromycin sterility. Microtiter plates were either inoculated immediately or wrapped and frozen at -70°C.
Inoculation of Strains into Microtiter Plates
Bacteria were prepared as indicated above and diluted 1/1000 in' BHI. The diluted test strain was poured into a sterile trough or petri dish. A multichannel pipettor was used to introduce 100/zl of this suspension to wells Al through H8. 100fd of this inoculum was also added to the appropriate control wells (see above). The final inoculum in the wells was 2~7 x 105 viable cells/ml, as determined by dilution and plating. The plates were shaken for 3 to 5 minutes on a Sarstedt TPM-2shaker at 500rpm. They were incubated overnight (approximately 15 hours) in a 37°C incubator. The turbidity in each well was observed with a mirrored plate reader (Titertek). For each plate, the lowest concentration of azithromycin that produced no growth was scored as the azithromycin MIC. The MICof the test compoundwas similarly defined. For the wells with test compoundplus azithromycin, the MICwas considered to be the combination which contained the lowest total concentration that inhibited growth of the test strain. The control wells were observed for appropriate growth or absence of growth. The solvent control wells in these assays produced growth of test organisms comparable to the growth control well. Synergy in these assays was defined as a >2 dilution difference between the MIC of azithromycin plus test compound as compared to the MIC of test compound or azithromycin alone15).
Acute Systemic Infections
The acute systemic infections were produced by ip administration of bacterial challenge to CF1 (Charles River) mixed sex mice (ll~13g).
The number of organisms injected was adjusted to provide an inoculum one to ten times the LD100. S. pyogenes ATCC12384 was grown overnight at 37°C in BHI broth, appropriately diluted and administered as a suspension in BHI broth.
S. aureus 01A129 was grown overnight on BHI agar containing erythromycin (5/ig/ml), washed off with sterile phosphate buffered saline, adjusted to a standard turbidity and suspended in sterile 5%hog gastric mucin prior to administration to mice. Survival was recorded over a 4-day period and the PD50 calculated from data obtained from a dose range consisting of four different antibiotic concentrations in a two-fold (S. aureus studies) or four-fold (S. pyogenes study) dilution series. Mice (10 per group) were treated subcutaneously at 0.5 and 4 hours after challenge. The 50% protective dose (PD50) was expressed in mg/kg/dose and calculated by the probit method1 6*.
Results and Discussion
Compounds of several structural types (Table 1) The MICof these inhibitors for a panel of known MLSB-resistant bacterial strains was determined (Table For each strain, the top row of numbers is the concentration of the test compoundplus the concentration of azithromycin that produce an MIC. The bottom row is the MICof the compound alone/MIC of azithromycin alone.
3). In these assays, the MIC of the inhibitor in combination with the macrolide, azithromycin, was compared to the MIC of the inhibitor alone and azithromycin alone. CP-29,474-22, did not inhibit the MLSB-resistant staphylococcal strains, but was active against the enterococcal and Group B streptococcal strains. It was also moderately active against the recombinant E. coli strain expressing MLSBresistance.
Azithromycin did not have a synergistic effect on the potency of CP-29,474-22 against these strains. CP-1 17,519-01 showed synergistic or additive activity with azithromycin against S. aureus 01A129 and E. faecalis 03A1029 in the assay. In contrast, ErmC inhibitors P-3025 and CP-74,932-04 were active as single agents against each of the bacterial strains. Both compounds had MICs of 3.1 to 6.25/xg/ml, and neither had a synergistic or additive effect with azithromycin. This was an unexpected result, since inhibition of the ErmC methylase would not a priori be expected to inhibit the growth of bacterial cells expressing this enzyme. Although these compounds did not inhibit the bacterial EcoRl methylase, which methylates an internal adenine residue within a specific hexanucleotide palindromic sequence on DNA,it is possible that they inhibit other bacterial transmethylases and that this effect is responsible for their potency as single agents. P-3025 and CP-74,932-04 were also inhibitory to macrolide-sensitive bacterial strains (data not shown years in areas where macrolide use has increased many MLSB-resistant strains have become constitutive, which usually occurs by a deletion in the 5' regulatory region5).
A second aspect of regulation may limit the production ofmethylase in cells with both inducible and constitutive MLSB-resistance. It has been observed that expression of the protein is autoregulated at the level of its own translation, and that certain methylase-deficient variants of ErmCwith mutations in the structural gene overproduce truncated forms of inactive methylase. This is consistent with a model in which active methylase regulates its own production by a feedback regulatory loop. The net effect of this is to bring the number of methylase molecules in the cell to a steady state which is approximately equal to the number of ribosomes per cell, 2~3 x lO418). Competitive or non-competitive inhibitors of enzymes produced constitutively would have to be present in higher concentrations to be effective.
One hundred and sixty thousand synthetic compounds were screened and small-molecule inhibitors of various NOV. 1995 structural types were identified as specific inhibitors of the dimethylation of 23S rRNA catalyzed by the ErmC methylase. Four of these had IC5Os < 5 jim and appeared to have little or no inhibitory activity against two unrelated methyltransferases. Someof these were able to penetrate into Gram-positive, and sometimes into Gram-negative, MLSB-resistant bacterial strains and inhibit growth (Table 3) , either alone or in synergy with a macrolide. Although most of these compoundshad no activity in mouse models of infection, they represent synthetic leads which may be utilized to design more potent, selective agents with pharmacokinetic properties suitable for use in human disease.
